Cargando…

Prevalence and clinical significance of clinically evident portal hypertension in patients with hepatocellular carcinoma undergoing transarterial chemoembolization

BACKGROUND: Clinically evident portal hypertension (CEPH) was previously identified as a prognostic factor for patients with hepatocellular carcinoma (HCC). However, little is known about the prognostic influence of CEPH on the long‐term outcome of patients with HCC undergoing transarterial chemoemb...

Descripción completa

Detalles Bibliográficos
Autores principales:	Müller, Lukas, Hahn, Felix, Mähringer‐Kunz, Aline, Stoehr, Fabian, Gairing, Simon Johannes, Foerster, Friedrich, Weinmann, Arndt, Galle, Peter Robert, Mittler, Jens, Pinto dos Santos, Daniel, Pitton, Michael Bernhard, Düber, Christoph, Fehrenbach, Uli, Auer, Timo Alexander, Gebauer, Bernhard, Kloeckner, Roman
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Hepatobiliary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8830270/ https://www.ncbi.nlm.nih.gov/pubmed/34918471 http://dx.doi.org/10.1002/ueg2.12188

Ejemplares similares

Immunonutritive Scoring for Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization: Evaluation of the CALLY Index
por: Müller, Lukas, et al.
Publicado: (2021)

Immunonutritive Scoring in Patients With Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization: Prognostic Nutritional Index or Controlling Nutritional Status Score?
por: Müller, Lukas, et al.
Publicado: (2021)

Refining Prognosis in Chemoembolization for Hepatocellular Carcinoma: Immunonutrition and Liver Function
por: Müller, Lukas, et al.
Publicado: (2021)

Hepatic vein tumor thrombosis in patients with hepatocellular carcinoma: Prevalence and clinical significance
por: Mähringer‐Kunz, Aline, et al.
Publicado: (2021)

Conventional transarterial chemoembolization versus drug-eluting bead transarterial chemoembolization for the treatment of hepatocellular carcinoma
por: Kloeckner, Roman, et al.
Publicado: (2015)

The Addition of Transarterial Chemoembolization to Palliative Chemotherapy Extends Survival in Intrahepatic Cholangiocarcinoma
por: Gairing, Simon Johannes, et al.
Publicado: (2021)

High pretreatment static and dynamic alpha‐fetoprotein values predict reduced overall survival in hepatocellular carcinoma
por: Czauderna, Carolin, et al.
Publicado: (2021)

Validation of the SNACOR clinical scoring system after transarterial chemoembolisation in patients with hepatocellular carcinoma
por: Mähringer-Kunz, Aline, et al.
Publicado: (2018)

(13)C-Methacetin Breath Test Predicts Survival in Patients With Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization
por: Gairing, Simon Johannes, et al.
Publicado: (2022)

Portal hypertension in patients with hepatocellular carcinoma and immunotherapy: prognostic relevance of CT-morphologic estimates
por: Müller, Lukas, et al.
Publicado: (2023)

Fully automated AI-based splenic segmentation for predicting survival and estimating the risk of hepatic decompensation in TACE patients with HCC
por: Müller, Lukas, et al.
Publicado: (2022)

Prediction of postembolization syndrome after transarterial chemoembolization of hepatocellular carcinoma and its impact on prognosis
por: Roehlen, Natascha, et al.
Publicado: (2023)

Transjugular Portosystemic Stent Shunt: Impact of Right Atrial Pressure on Portal Venous Hemodynamics Within the First Week
por: Pitton, Michael Bernhard, et al.
Publicado: (2021)

Baseline Splenic Volume Outweighs Immuno-Modulated Size Changes with Regard to Survival Outcome in Patients with Hepatocellular Carcinoma under Immunotherapy
por: Müller, Lukas, et al.
Publicado: (2022)

Radiomics-Based Prediction of Future Portal Vein Tumor Infiltration in Patients with HCC—A Proof-of-Concept Study
por: Stoehr, Fabian, et al.
Publicado: (2022)

The prognostic role of early tumor shrinkage in patients with hepatocellular carcinoma undergoing immunotherapy
por: Müller, Lukas, et al.
Publicado: (2022)

Selective internal radiotherapy (SIRT) versus transarterial chemoembolization (TACE) for the treatment of intrahepatic cholangiocellular carcinoma (CCC): study protocol for a randomized controlled trial
por: Kloeckner, Roman, et al.
Publicado: (2014)

Survival Prediction in Intrahepatic Cholangiocarcinoma: A Proof of Concept Study Using Artificial Intelligence for Risk Assessment
por: Müller, Lukas, et al.
Publicado: (2021)

Randomized Comparison of Selective Internal Radiotherapy (SIRT) Versus Drug-Eluting Bead Transarterial Chemoembolization (DEB-TACE) for the Treatment of Hepatocellular Carcinoma
por: Pitton, Michael B., et al.
Publicado: (2014)

Prediction of regional lymph node metastasis in intrahepatic cholangiocarcinoma: it’s not all about size
por: Kolck, Johannes, et al.
Publicado: (2023)

The unmet need of personalized HCC screening—Lessons learned from the Swedish nationwide registries
por: Gairing, Simon Johannes, et al.
Publicado: (2022)

Tumor Burden in Patients With Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization: Head-to-Head Comparison of Current Scoring Systems
por: Müller, Lukas, et al.
Publicado: (2022)

Current Strategies to Identify Patients That Will Benefit from TACE Treatment and Future Directions a Practical Step-by-Step Guide
por: Müller, Lukas, et al.
Publicado: (2021)

Portosystemic shunt surgery in the era of TIPS: imaging-based planning of the surgical approach
por: Fehrenbach, Uli, et al.
Publicado: (2020)

Survival prediction for patients with non-resectable intrahepatic cholangiocarcinoma undergoing chemotherapy: a retrospective analysis comparing the tumor marker CA 19-9 with cross-sectional imaging
por: Hahn, Felix, et al.
Publicado: (2020)

The impact of portal vein tumor thrombosis on survival in patients with hepatocellular carcinoma treated with different therapies: A cohort study
por: Mähringer-Kunz, Aline, et al.
Publicado: (2021)

Addition of Camrelizumab to Transarterial Chemoembolization in Hepatocellular Carcinoma With Untreatable Progression
por: Ren, Yanqiao, et al.
Publicado: (2022)

Initiative on Superselective Conventional Transarterial Chemoembolization Results (INSPIRE)
por: de Baere, Thierry, et al.
Publicado: (2022)

Distant Metastases in Patients with Intrahepatic Cholangiocarcinoma: Does Location Matter? A Retrospective Analysis of 370 Patients
por: Hahn, Felix, et al.
Publicado: (2020)

Clinical application of the contrast-enhancement boost technique in computed tomography angiography of the portal vein
por: Hou, Juan, et al.
Publicado: (2022)

Hepatocellular adenomas: is there additional value in using Gd-EOB-enhanced MRI for subtype differentiation?
por: Auer, Timo Alexander, et al.
Publicado: (2020)

Predicting the prognosis of hepatocellular carcinoma with the treatment of transcatheter arterial chemoembolization combined with microwave ablation using pretreatment MR imaging texture features
por: Liu, Jun, et al.
Publicado: (2021)

Gd-EOB MRI for HCC subtype differentiation in a western population according to the 5(th) edition of the World Health Organization classification
por: Auer, Timo A., et al.
Publicado: (2023)

Risk Stratification in Advanced Biliary Tract Cancer: Validation of the A.L.A.N. Score
por: Müller, Lukas, et al.
Publicado: (2020)

Decision making for transjugular intrahepatic portosystemic stent shunt in refractory ascites and variceal bleeding: MELD, or not MELD, that is the question
por: Pitton, Michael B., et al.
Publicado: (2020)

Impact of thyroid disorders on the incidence of non‐alcoholic fatty liver disease in Germany
por: Labenz, Christian, et al.
Publicado: (2021)

Diagnostic accuracy of intermediate b-value diffusion-weighted imaging for detection of residual hepatocellular carcinoma following transarterial chemoembolization with drug-eluting beads
por: Hassan, Ahmed E, et al.
Publicado: (2019)

Liver segmental volume and attenuation ratio (LSVAR) on portal venous CT scans improves the detection of clinically significant liver fibrosis compared to liver segmental volume ratio (LSVR)
por: Obmann, V. C., et al.
Publicado: (2020)

Portal hypertension and hepatocellular carcinoma: Navigating uncharted waters
por: Sidali, Sabrina, et al.
Publicado: (2022)

Clinical management of patients with drug‐induced liver injury (DILI)
por: Björnsson, Einar S.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_9gg2nl6lakv3h2eje5roou29sf